In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on MiNK Therapeutics (INKT – Research Report), with a price target of $10.00. The company’s shares opened today at $1.83.
Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Gracell Biotechnologies, and Context Therapeutics. According to TipRanks, Bodnar has an average return of -8.4% and a 35.14% success rate on recommended stocks.
MiNK Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $8.33.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $4.32 and a one-year low of $0.85. Currently, MiNK Therapeutics has an average volume of 122.9K.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INKT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other life-threatening illnesses.
Read More on INKT:
